New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
10:07 EDTARIA, RAX, EXA, SVLC, SHTDF, PANW, E, MERC, SOL, PCAR, UFS, SBMRYOn The Fly: Analyst Upgrade Summary
Domtar (UFS) upgraded to Buy from Neutral at Goldman... Eni SpA (E) upgraded to Outperform from Market Perform at Raymond James... Exa Corp. (EXA) upgraded to Outperform from Neutral at RW Baird... PACCAR (PCAR) upgraded to Buy from Neutral at Goldman... Palo Alto (PANW) upgraded to Outperform from Market Perform at FBR Capital... Rackspace (RAX) upgraded to Overweight from Equal Weight at Morgan Stanley... ReneSola (SOL) upgraded to Buy from Neutral at Roth Capital... Sinopharm Group (SHTDF) upgraded to Outperform from Neutral at Credit Suisse... ARIAD (ARIA) at H.C upgraded to Buy from Neutral at H.C. Wainwright... SilverCrest (SVLC) upgraded to Buy from Neutral at Roth Capital... Mercer (MERC) upgraded to Hold from Reduce at TD Securities... SABMiller (SBMRY) upgraded to Outperform from Market Perform at Bernstein.
News For UFS;E;EXA;PCAR;PANW;RAX;SOL;SHTDF;ARIA;MERC;SVLC;SBMRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 12, 2014
06:41 EDTEEni SpA to suspend efforts to unload stake in oil services unit, NY Times says
Subscribe for More Information
December 11, 2014
14:55 EDTRAXRackspace management to meet with William Blair
Subscribe for More Information
12:02 EDTPANWPalo Alto to host special shareholder meeting
Subscribe for More Information
10:51 EDTPANWPalo Alto management to meet with Piper Jaffray
Subscribe for More Information
10:13 EDTPCAROn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:13 EDTARIAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARIAD (ARIA) downgraded at Credit Suisse... AbbVie (ABBV) downgraded to Equal Weight from Overweight at Morgan Stanley... Aimco (AIV) downgraded to Hold from Buy at KeyBanc... Anglo American (AAUKY) downgraded to Underperform from Neutral at Exane BNP Paribas... Approach Resources (AREX) downgraded at Sterne Agee... CommVault (CVLT) downgraded to Neutral from Outperform at Macquarie... Fifth Street Senior (FSFR) downgraded to Perform from Outperform at Oppenheimer... Harmonic (HLIT) downgraded to Neutral from Buy at Sidoti... Macerich (MAC) downgraded to Hold from Buy at Deutsche Bank... Newell Rubbermaid (NWL) downgraded to Outperform from Strong Buy at Raymond James... Olin Corp. (OLN) downgraded at Longbow... Penn West (PWE) downgraded to Underperform from Neutral at BofA/Merrill... Prudential plc (PUK) downgraded to Neutral from Buy at Nomura... Semiconductor Manufacturing (SMI) downgraded to Hold from Buy at Jefferies... Suncor (SU) downgraded to Neutral from Buy at BofA/Merrill... Talisman Energy (TLM) downgraded to Underperform from Neutral at BofA/Merrill... Thompson Creek (TC) downgraded to Hold from Buy at Deutsche Bank... Toll Brothers (TOL) downgraded to Underperform from Sector Perform at RBC Capital... Travelers (TRV) downgraded to Neutral from Buy at UBS... United Therapeutics (UTHR) downgraded at Credit Suisse... Vera Bradley (VRA) downgraded to Underperform from Neutral at Sterne Agee.
09:16 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTARIAARIAD downgraded at Credit Suisse
As previously reported, Credit Suisse downgraded ARIAD to Underperform from Neutral. The firm said Iclusig launch metrics are weak and expects it to remain a last option for CML patients with specific resistant mutations or failure with other therapies. Price target lowered to $6 from $8.
07:34 EDTRAXBarclays to hold a bus tour
Subscribe for More Information
06:52 EDTPCARPACCAR initiated with a Buy at Global Hunter
Subscribe for More Information
06:14 EDTARIAARIAD downgraded to Underperform from Neutral at Credit Suisse
Subscribe for More Information
December 10, 2014
08:16 EDTPANWBarclays to hold a conference
Global Technology Conference is being held in San Francisco on December 9-10 with webcasted company presentations to begin on December 10 at 10:40 am; not all company presentations may be webcasted.Webcast Link
08:12 EDTPANWIT security outlook remains positive, says Pacific Crest
Subscribe for More Information
December 9, 2014
14:10 EDTPCARPACCAR near highs of session, up over 1.6%
14:07 EDTPCARPACCAR says Class 8 truck orders through November up 46% YoY
Subscribe for More Information
14:00 EDTPCARPACCAR declares extra cash dividend of $1.00 per share
Subscribe for More Information
09:10 EDTARIAARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:37 EDTARIAARIAD announces safety, efficacy follow-up data on Iclusig
Subscribe for More Information
07:36 EDTARIAARIAD says Iclusig shows anti-leukemic activity in long-term follow up data
ARIAD Pharmaceuticals announced long-term follow up data from the Phase 1 trial of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The study now shows that with a median follow-up of four years in chronic phase CML patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients with 72 percent having a major cytogenetic response, 65 percent having a complete cytogenetic response and 56 percent having a major molecular response. Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events. These data were featured in a poster presentation on December 8 at the 56th Annual Meeting of the American Society of Hematology taking place in San Francisco.
December 8, 2014
07:36 EDTARIAARIAD: Iclusig demonstrates anti-leukemic activity in patents in Phase 2 trial
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use